Moderna-Merck vaccine cuts odds of skin cancer recurrence in half, study finds
A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday. Those with severe melanomas who received the vaccine and Merck’s cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda,
Read More